Glaxosmithkline LLC

Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Alexander Harrison Taylor

John Richard White

Yu Xue

Ian Kirby

Yuan Zhu

Zdenka Ludmila Jonak

Kyung Oh Johanson

Stephen H Trulli

Thomas Matthew Webb

Judithann M Lee

Neil James Clarke

Pramathesh S Patel

Yong Hwan Jin

Yu Xu

Christopher B Hopson

Zdenka Haskova

James D Jowett

Alan R Gardner

Thomas D Sweitzer

The present invention provides genetically modifiedstrains wherein at least one nucleic acid sequence encoding a functional gene product and/or at least one nucleic acid sequence necessary for expression of at least one functional gene product in saidstrain is genetically modified, wherein said gene product is responsible for proteolysis and/or glycosylation in said genetically modifiedstrain. In particular,strains are provided wherein nucleic acid sequence encoding a functional gene product or expression of said gene product are genetically modified: PEP4, PRB1, YPS1, YPS2, YMP1, YMP2, YMP3 and PMT4. Also provided herein are genetically modified host cells wherein wild type parent of said genetically modified host cell comprises a gene encoding a polypeptide having at least 60% sequence identity to amino acids 1-865 of SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:8 wherein said gene is genetically modified in the genome of said host cell such that the gene product is reduced or eliminated in said genetically modified host cell compared with said wild type host cell.

Host cells and methods of use

The invention relates to antibodies which treat diseases in which human IL-8, Gro-alpha, Gro-beta, Gro-gamma, GCP-2, and/or ENA-78 are implicated.

Antibodies against the CXC-ELR family of chemokines

Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis.

CD127 binding proteins

The present disclosure relates to antigen binding proteins, such as antibodies, that bind to HER3, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present disclosure also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic, gastric, melanoma and other cancers that overexpress HER3.

Antigen binding proteins

The present invention relates to methods of preventing glyconoylation of polypeptides produced in micororganisms.

Methods for reducing gluconoylation of proteins

Growing community of inventors

King of Prussia, PA, United States of America

Alexander Harrison Taylor